Idiosyncratic Drug-induced Liver Injury Study (DILIGEN)
The international Drug-induced Liver Injury Consortium (iDILIC), is studying the genetic susceptibility to idiosyncratic drug-induced liver injury. The UK arm of the study is DILIGEN. The study, involves collecting DNA from cases and suitable controls for a genome wide association study (GWAS) with the aim of identifying polymorphisms predictive of the development of drug-related liver injury and hence allowing the possibility of prevention. We will be grateful to physicians treating idiosyncratic drug-induced liver injury cases, particularly BSG members, to put us in contact with suitable patients.
Patients who developed one of the following due to drug-induced liver injury are suitable to be included: